Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

英語社名 Kufu Company Inc. 会社サイトhttps://kufu.jp/ 概要 毎日のくらしに係る日常生活関連のメディア運営。住まい・結婚関連事業。

糖尿病の合併症であるDMEは、重度の視力低下や失明につながる可能性があります ... 変更には、業界のベテランであるフレッド・ハッサンの任命と、メルク・アンド・カンパニーでのフルタイムの役職への移行に伴うアンソニー・P・アダミス医学博士と ...

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic ...

DESERT MOUNTAIN ENERGY CORP. (the "Company") (TSXV: DME) (U.S. OTC: DMEHF) (Frankfurt: QM01) From the President of the Company. Desert Mountain Energy is pleased to announce that the West Pecos Slope ...

Announced positive interim data for DURAVYU 2.7mg in DME demonstrating meaningful, early and sustained visual acuity gains, strong anatomical ...

主役の3人も魅力的でいつの間にか応援したくなる作品 女性のコミュニティー、結束力はすごい。 会社に勤めている人であれば分かるだろう。 それを遺憾なく発揮していた。 全てにおいて、なんとも懐かしさが湧き上がるビジュアルと社会観。このような ...

Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial ...

Full topline results are anticipated in early 2025, with ongoing pivotal trials for wet AMD and DME. According to the company, Duravyu 2.7 mg demonstrated an early and sustained anatomical improvement ...

BioCryst ( (BCRX) ) has issued an announcement. BioCryst Pharmaceuticals reported a strong Q3 2024 with ORLADEYO net revenue ...

OneroRx, a leading regional provider of pharmacy and telepharmacy services, has acquired two EverCare Pharmacy locations in Princeton and Trenton, Mo., effective Nov. 1.

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Good day and Welcome to the BioCryst Third Quarter 2024 Earnings ...